The US healthcare system under Trump 2.0 are likely to benefit Indian players, except for the push for increased US drug ...

JM Financial expects IndiGo's margins to improve sequentially, supported by lower fuel prices and double-digit ASK growth per ...

While the attendees are gradually navigating to snow-covered New Orleans for NADA Show 2025, JM&A Group is also gearing up to ...

During Trump’s 2017-2021 tenure, Indian pharma equities faced challenges, including increased FDA regulatory actions that ...

JM Financial reinitiated coverage on the stock with a ‘buy’ rating and target price of INR 1,250, signaling an upside ...

Zomato shares jumped 3% to INR 248.65 apiece on the BSE after JM Financial reiterated its ‘buy’ rating on the stock.